Bioxytran Stock

Bioxytran ROE

The Return on Equity (ROE) of Bioxytran (BIXT) as of Aug 17, 2026 is 146.03 %. In the previous year, Return on Equity (ROE) was 87.68 % — a change of 66.56% (higher).

ROE

146.03 %

YoY

66.56%

Last updated:

In 2026, Bioxytran's return on equity (ROE) was 146.03 %, a 66.56% increase from the 87.68 % ROE in the previous year.

Access this data via the Eulerpool API

Bioxytran Stock analysis

What does Bioxytran do? Bioxytran Inc. is a US-based company specialized in the development of medical therapies based on the use of oxygen transport molecules. The company's patented platform technology focuses on the development of new innovative therapies for treating central nervous system disorders, cardiovascular diseases, and cancer treatment. The company was founded in 2014 by a group of scientists and entrepreneurs aiming to create a transformative medical product that improves oxygen transport in the body and enables the treatment of severe diseases. Bioxytran's platform is based on the use of perfluorocarbon compounds (PFCs) that have a strong affinity for oxygen and can bind and transport it in the blood. The company's business model is centered on the development and commercialization of new therapies to treat diseases such as stroke, heart attack, cancer, and even COVID-19. By improving oxygen transport in the body, Bioxytran aims to enhance the effectiveness of medical treatments and create new therapeutic possibilities. The company's focus areas include stroke treatment, where they have developed a technology that allows direct oxygen transport to the affected brain tissue, minimizing neural damage and enabling faster recovery. They have also developed a new type of heart attack treatment that aims to improve blood flow and eliminate oxygen deficiency in the heart, as well as another therapy option for patients suffering from acute heart attacks. In the field of cancer treatment, Bioxytran has a promising therapy in the pipeline based on PFCs that can selectively target cancer cells, potentially making chemotherapy more effective and patient-friendly. Overall, Bioxytran's goal is to develop medical therapies that have the potential to revolutionize the treatment of severe diseases. They offer a range of products and approaches that have the potential to improve the lives of many patients. In summary, Bioxytran Inc. is an emerging company in the field of medical therapies, driven by innovation and technological expertise. Their focus on developing high-potential products that improve oxygen transport in the body facilitates the treatment of severe diseases. With their various divisions and products, Bioxytran is able to address a broad spectrum of medical needs. Bioxytran is one of the most popular companies on Eulerpool.

ROE Details

Decoding Bioxytran's Return on Equity (ROE)

Bioxytran's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Bioxytran's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Bioxytran's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Bioxytran’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Bioxytran stock

Return on Equity (ROE) of Bioxytran is 146.03 % in 2026.

Return on Equity (ROE) of Bioxytran changed from 87.68 % to 146.03 %, representing a 66.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Bioxytran since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Bioxytran with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Bioxytran

All Key Metrics — Bioxytran